Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) announced a virtual event on December 10, 2022, at 12:00 p.m. ET, to discuss initial data from the Phase 2 SELECT-AML-1 clinical trial focusing on unfit acute myeloid leukemia (AML). The event will feature Syros management and Dr. Daniel Pollyea from the University of Colorado, highlighting the trial's initial findings and future plans. Initial data will also be presented at the 64th American Society of Hematology Annual Meeting on the same date. Participants can register for the event and access a live webcast.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML). The event will be held on Saturday, December 10, 2022 beginning at 12:00 p.m. ET.

The event will feature presentations by Syros management, who will review the initial SELECT-AML-1 data and plans for the randomized portion of the Phase 2 trial, as well as Daniel Pollyea, M.D., M.S., Associate Professor of Medicine, Clinical Director of Leukemia Services, University of Colorado School of Medicine, who will provide his perspective on the evolving treatment landscape.

Participants can register for the event here. In addition, a live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

Initial data from the SELECT-AML-1 trial will also be presented on Saturday, December 10, 2022 in a poster session at the 64^th American Society of Hematology (ASH) Annual Meeting.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221205005039/en/

Syros

Karen Hunady

Director of Corporate Communications & Investor Relations

1-857-327-7321

khunady@syros.com



Media

Brittany Leigh, Ph.D.

LifeSci Communications, LLC

+1-813-767-7801

bleigh@lifescicomms.com



Investors

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

What is the SELECT-AML-1 clinical trial being conducted by Syros Pharmaceuticals (SYRS)?

The SELECT-AML-1 clinical trial is a Phase 2 trial focusing on patients with newly diagnosed, unfit acute myeloid leukemia (AML), examining the safety and efficacy of Syros' treatments.

When will Syros Pharmaceuticals present initial data from the SELECT-AML-1 trial?

Syros Pharmaceuticals will present initial data from the SELECT-AML-1 trial on December 10, 2022, during a virtual event and at the 64th American Society of Hematology Annual Meeting.

Who will participate in the virtual event on December 10, 2022, for Syros Pharmaceuticals (SYRS)?

The virtual event will feature Syros management and Dr. Daniel Pollyea, who will discuss the trial's initial data and the treatment landscape for AML.

How can I register for the virtual event hosted by Syros Pharmaceuticals on December 10, 2022?

Participants can register for the virtual event on the Syros Pharmaceuticals website or via the provided registration link in their press release.

What additional resources will be available during the Syros Pharmaceuticals event on December 10, 2022?

A live webcast of the event will be available, and an archived replay will be accessible for approximately 30 days following the presentation.